Unstoppable antidiabetic ‘Zemiglo’ passing KRW 7 billion prescriptions a month
‘Zemiglo,’ a novel antidiabetic developed for the first time in Korea, passed KRW 7 billion prescriptions a month.
According to UBIST, a pharmaceutical information company, LG Chem’s ‘Zemiglo’ passed KRW 7 billion outpatient prescriptions last September.
After passing KRW 6 billion on May this ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
